INSM
Price
$67.49
Change
+$1.47 (+2.23%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
12.05B
68 days until earnings call
MNKD
Price
$4.12
Change
-$0.05 (-1.20%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
1.28B
74 days until earnings call
Interact to see
Advertisement

INSM vs MNKD

Header iconINSM vs MNKD Comparison
Open Charts INSM vs MNKDBanner chart's image
Insmed
Price$67.49
Change+$1.47 (+2.23%)
Volume$26.97K
Capitalization12.05B
MannKind
Price$4.12
Change-$0.05 (-1.20%)
Volume$22.98K
Capitalization1.28B
INSM vs MNKD Comparison Chart
Loading...
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INSM vs. MNKD commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INSM is a Buy and MNKD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (INSM: $66.02 vs. MNKD: $4.17)
Brand notoriety: INSM and MNKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INSM: 0% vs. MNKD: 0%
Market capitalization -- INSM: $12.05B vs. MNKD: $1.28B
INSM [@Biotechnology] is valued at $12.05B. MNKD’s [@Biotechnology] market capitalization is $1.28B. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INSM’s FA Score shows that 1 FA rating(s) are green whileMNKD’s FA Score has 0 green FA rating(s).

  • INSM’s FA Score: 1 green, 4 red.
  • MNKD’s FA Score: 0 green, 5 red.
According to our system of comparison, INSM is a better buy in the long-term than MNKD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INSM’s TA Score shows that 5 TA indicator(s) are bullish while MNKD’s TA Score has 5 bullish TA indicator(s).

  • INSM’s TA Score: 5 bullish, 2 bearish.
  • MNKD’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, INSM is a better buy in the short-term than MNKD.

Price Growth

INSM (@Biotechnology) experienced а -1.79% price change this week, while MNKD (@Biotechnology) price change was -8.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.05%. For the same industry, the average monthly price growth was +3.15%, and the average quarterly price growth was -3.91%.

Reported Earning Dates

INSM is expected to report earnings on Jul 31, 2025.

MNKD is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INSM($12.1B) has a higher market cap than MNKD($1.28B). INSM YTD gains are higher at: -4.374 vs. MNKD (-35.148). MNKD has higher annual earnings (EBITDA): 82.6M vs. INSM (-917.87M). INSM has more cash in the bank: 1.2B vs. MNKD (182M). MNKD has less debt than INSM: MNKD (47.2M) vs INSM (1.14B). INSM has higher revenues than MNKD: INSM (381M) vs MNKD (298M).
INSMMNKDINSM / MNKD
Capitalization12.1B1.28B943%
EBITDA-917.87M82.6M-1,111%
Gain YTD-4.374-35.14812%
P/E RatioN/A42.20-
Revenue381M298M128%
Total Cash1.2B182M659%
Total Debt1.14B47.2M2,422%
FUNDAMENTALS RATINGS
INSM vs MNKD: Fundamental Ratings
INSM
MNKD
OUTLOOK RATING
1..100
7658
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
54
Fair valued
PROFIT vs RISK RATING
1..100
2446
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4484
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNKD's Valuation (54) in the Biotechnology industry is somewhat better than the same rating for INSM (94). This means that MNKD’s stock grew somewhat faster than INSM’s over the last 12 months.

INSM's Profit vs Risk Rating (24) in the Biotechnology industry is in the same range as MNKD (46). This means that INSM’s stock grew similarly to MNKD’s over the last 12 months.

INSM's SMR Rating (100) in the Biotechnology industry is in the same range as MNKD (100). This means that INSM’s stock grew similarly to MNKD’s over the last 12 months.

INSM's Price Growth Rating (44) in the Biotechnology industry is somewhat better than the same rating for MNKD (84). This means that INSM’s stock grew somewhat faster than MNKD’s over the last 12 months.

MNKD's P/E Growth Rating (98) in the Biotechnology industry is in the same range as INSM (100). This means that MNKD’s stock grew similarly to INSM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INSMMNKD
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 8 days ago
69%
Bullish Trend 24 days ago
82%
Declines
ODDS (%)
Bearish Trend 10 days ago
75%
Bearish Trend 3 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CGSD25.830.02
+0.08%
Capital Group Short Duration Income ETF
EFA87.97N/A
N/A
iShares MSCI EAFE ETF
DMAR38.43N/A
N/A
FT Vest US Equity Deep Bffr ETF Mar
MEMX30.47N/A
N/A
Matthews Emerging Markets Ex Chn Act ETF
GCC19.73N/A
N/A
WisdomTree Enhanced Commodity Stgy Fd

INSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INSM has been closely correlated with THAR. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then THAR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INSM
1D Price
Change %
INSM100%
N/A
THAR - INSM
74%
Closely correlated
+1.48%
AGIO - INSM
45%
Loosely correlated
-1.73%
SRPT - INSM
44%
Loosely correlated
-3.15%
VERA - INSM
41%
Loosely correlated
N/A
AXON - INSM
40%
Loosely correlated
N/A
More

MNKD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with VCYT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNKD
1D Price
Change %
MNKD100%
N/A
VCYT - MNKD
44%
Loosely correlated
N/A
LXRX - MNKD
42%
Loosely correlated
N/A
INSM - MNKD
40%
Loosely correlated
N/A
BLUE - MNKD
38%
Loosely correlated
+0.40%
GBIO - MNKD
37%
Loosely correlated
-3.38%
More